Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -10.78
- Piotroski Score 2.00
- Grade Buy
- Symbol (KZIA)
- Company Kazia Therapeutics Limited
- Price $0.43
- Changes Percentage (9.03%)
- Change $0.04
- Day Low $0.39
- Day High $0.45
- Year High $1.58
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 09/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.37
- Trailing P/E Ratio -0.67
- Forward P/E Ratio -0.67
- P/E Growth -0.67
- Net Income $-20,465,180
Income Statement
Quarterly
Annual
Latest News of KZIA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Kazia Therapeutics Limited (KZIA) Stock Price, News, Quote & History
Kazia Therapeutics Limited, an oncology-focused biotech company, is developing Paxalisib for glioblastoma and EVT801 for vascular endothelial growth factor receptor 3. Established in 1994 in Sydney, A...
By Yahoo! Finance | 2 months ago
